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INTRODUCTION 
 
 
 Lung cancer was considered to be rare in the beginning of 
the century but has now reached almost epidemic proportions. It is 
the leading cause of cancer deaths in developed countries and is 
also rising at alarming rates in developing countries. It is the 
leading cause of cancer mortality in most of the countries in the 
world. It remains the most lethal form of cancer in men and has 
now surpassed breast cancer in women as well in USA, where 
170,000 new cases are diagnosed per year.  
 The  Indian subcontinent in South Asia occupies 2.4% of the 
world land mass and is home to 16.5% of the world population. 
India is a vast rural panorama with 70% of the population residing 
in villages in rural surroundings. The worldwide incidence of lung 
cancer is 14% whereas it constitutes 6.8% of all cancers in India.10 
Non-small cell lung cancer accounts for nearly 85% and small cell 
lung cancer accounts for 15% to 20% of cases. There are important 
differences in the clinical spectrum of lung cancer patients in India 
compared to those in the West. Both the mean and peak ages of 
lung cancer are lower. The smoker: non-smoker ratios have been 
lower in most of the Indian studies as compared to those in the 
West. Though there is increased awarness of hazards of smoking in 
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developed countries that shows some decline in smoking habits, in 
India lack of knowledge and awareness of hazards of smoking 
actually increases the number of smokers and thereby increases the 
incidence of lung cancer. 
 Despite advances in imaging techniques and treatment 
modalities, the prognosis of lung cancer remains poor, with a five-
year survival of 14% in early stages and less than 5% in locally 
advanced stages. Unfortunately only 20-30% of patients present 
with an operable disease, while most of the patients present in an 
advanced stage II and III. The main reason for late presentation in 
our country is the poor health awareness, delayed recognition and 
the poor referral of patients to the specialised centers.  
 Almost all patients present with symptoms of lung cancer 
that they were found to be in an advanced stage of lung cancer. 
Screening for lung cancer is still a controversy worldwide, is not 
feasible in our country. And especially in tertiary Government 
hospital set up, where every patient are only poor, screening could 
not be done because of their poor affordability. 
  The present study was undertaken to analyse the clinical 
presentation, radiological pattern and pathological characteristics 
of lung cancer at Government Rajaji Hospital, Madurai.  
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AIMS AND OBJECTIVES 
• To study the clinical pattern of lung cancer, with 
special emphasis to study the most common clinical 
presentation. 
 
• To study through the clinical presentation, the extent of 
disease.  
 
• To confirm the diagnosis and to stage them with 
Imaging, Bronchoscopy and Biopsy. 
 
• To study about the distribution of lobe pattern involved 
in primary lung cancer. 
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REVIEW OF LITERATURE 
 
HISTORY 
 
 Some 150 years ago, it was an extremely rare disease. In 
1878, malignant lung tumors represented only 1% of all cancers. 
By 1918, the percentage had risen to almost 10% and by 1927 to 
more than 14%7. The smoking of cigarettes had become popular 
shortly before the turn of the century. Originally, cigarettes were 
hand rolled and this made them expensive. In 1876, the cigarette 
manufacturer Allen & Ginter offered a prize for the development of 
a machine that would speed up the process. James Albert Bonsack 
developed a machine that could make 70,000 cigarettes in a 10 h 
day. World War I helped to popularize the smoking of cigarettes.  
Soldiers in the trenches smoked to relieve stress, and so did many 
civilians.  
 The link between the smoking of cigarettes and lung cancer 
began to be suspected by clinicians in the 1930s when they noted 
the increase of this "unusual" disease. Publications began to appear 
and about 2 decades later the role of smoking as causative agent 
had been firmly established. A case control study was published in 
1940 in Germany and its author flatly stated that "the 
extraordinary rise in tobacco use was the single most important 
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cause of the rising incidence of lung cancer" (Müller, 1940). At 
this time, lung cancer had become the second most frequent cause 
of cancer death, stomach cancer being the first. In 1943, the 
German Institute for Tobacco Hazards Research disclosed a study 
which found that among 109 lung cancer cases only 3 were 
nonsmokers,  a proportion much lower than in the control group. In 
the 1950s Doll and Hill in England and Cuyler Hammond and 
Ernest Wynder in the U.S. provided further evidence for a causal 
association between smoking and lung cancer. Yet, it took a long 
time until  the truth was fully accepted. Smokers, including many 
physicians,  who enjoyed cigarettes could or would not want to 
imagine or refused to believe that the habit (addiction would be 
more appropriate) was detrimental to their health. In the following 
decades, smoking continued to be "enjoyed" by hundreds of 
thousands until, after the first  report of the Surgeon General in 
1964, public awareness woke up and smoking became recognized 
as the hazard it is.  
  There was, however, one lung cancer where it had been 
obvious for a long time that it might be caused by an external 
agent.  As early as 1500, attention was called to this particular 
condition. In two regions of Germany and Czechoslovakia, 
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Schneeberg and Joachimsthal, there were productive mines, 
yielding first silver,  later nickel, cobalt, bismuth, and arsenic. The 
word "dollar"  actually stems from the word "Thaler;" coins minted 
from the pure silver of Joachimsthal were called "Joachimsthaler" 
(i.e.,  originating from Joachimsthal) or, abbreviated, "Thaler." The 
miners working these mines developed almost invariably a deadly 
disease, called "Bergkrankheit" (mountain sickness). Between 1876 
and 1938, 60 to 80% of all miners died from the disease which, on 
average, lasted 25 years. Certain regions of the mines were known 
as "death pits," where all workers got sick. As a result, lung cancer 
in miners was recognized as an occupational disease—and the 
miners therefore entitled for compensation—in 1926 in Germany 
and in 1932 in Czechoslovakia. While it was thought that chemical 
constituents of the ore that was produced, most notably arsenic, 
might be involved in the etiology of these lung cancers, it was 
early on suspected that "radium emanation" was the main culprit. 
Measurements published in 1924 in a German physics journal 
confirmed that the air in the mines contained high concentrations 
of radon gas, the highest more than 18,000 picocuires per liter.   
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DESCRIPTIVE EPIDEMIOLOGY 
 
 At the end of the 20th century, lung cancer had become one 
of the world’s leading causes of preventable death.  It  was a rare 
disease at the start of that century, but exposures to new etiologic 
agents and an increasing lifespan combined to make lung cancer a 
scourge of the 20th century. While tobacco had been widely used 
throughout the world for centuries, the present pandemic of lung 
cancer followed the introduction of manufactured cigarettes with 
addictive properties, which resulted in a new pattern of sustained 
exposure of the lung to inhaled carcinogens.  
 
 There is a great variation in the prevalence of lung cancer in 
different geographical areas. Nearly 70% of all the new cases of 
lung cancer in the world occur in the developed countries. USA, 
Canada, New Zealand (Maori population) and Europe have the 
highest incidence (>50 per 105 population) followed by China, 
Ireland, Malta, Spain, Australia, and New Zeland (non - Maori 
population) with a moderate incidence (35-50 per 105 population) 
and low incidence (<35 per 105 population) countries include Utah 
(USA), Latin America, most Asian countries, lceland, Norway and 
Sweden. This is the most frequent tumour in males, and 2nd or 3rd 
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most common in females. In the US alone, there were about 
1,64,100 new cases in 2000, of which 70,000 were in the 
metastatic stage (stage IV) and another 70,000 were locally 
advanced (stage IIIA and IIIB disease). In the European Union, the 
crude incidence of lung cancer is 52.2 cases per 105 per year and 
the death rate is 48.7 per 105 per year. For men, the rates are 79.3 
and 78.3 and for women, 21.6 and 20.5 respectively per 105 per 
year. Non-small cell lung cancer accounts for about 80% of all 
lung cancer cases. 
 
 Some of the increases compared to that prior to 1950, may be 
due to improved diagnosis but changes more recently reflect an 
actual increase. In 1980, it was estimated to cause 15.8% of all 
new cancer cases in males varying between 4.5% in Africa to 
23.3% in Europe. In females lung cancer is rare. However, the 
increase between 1975 and 1980 was 10.1% in males, but 16% in 
females. The situation was different in 1985. Ignoring the non-
melanoma skin cancers, lung cancer was estimated to be the most 
common cancer in men in the world around 1985. It comprised 
17.6% of all new cancers in men and 5.8% in women. In men there 
were about 667,000 new cases in 1985, and 219,000 in women. The 
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age adjusted mortality trends in 14 countries show that the increase 
is universal, at rates between one and five percent a year. Although 
the overall mortalities are less in females, marked increases have 
been seen in some countries, such as Canada, Denmark, and USA. 
 
PATHOPHYSIOLOGY 
Smoking 
 A single etiologic agent, cigarette smoking, is by far the 
leading cause of lung cancer, accounting for approximately 90% of 
lung cancer cases. Compared to never-smokers, smokers have about 
a 20-fold increase in lung cancer risk at present. Beedi smoking is 
more commonly seen among Indians of low socioeconomic groups 
and it is more carcinogenic than cigarette14. Passive smokers 
inhale a complex mixture of smoke that is now widely referred to 
as environmental tobacco smoke  .  
 
 In the initial decades of the smoking-caused epidemic of lung 
cancer, squamous cell carcinoma was the most frequent type of 
lung cancer that was observed in the population among smokers,  
and small cell carcinoma was the next most frequent. In the late 
1970s, the first evidence of a shift toward a predominance of 
adenocarcinoma was noted, and now adenocarcinoma of the lung is 
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the most common histologic type of lung cancer. In women, the 
Surveillance, Epidemiology, and End Results program data from 
1973 to 1996 indicate that the incidence rates of squamous cell,  
small cell, and large cell carcinomas have at  least reached a 
plateau while the rate for adenocarcinoma is still rising. 
Occupation 
 
 Certain occupations carry a higher risk of lung cancer. The 
following occupational exposures are known to be associated with 
an increased risk: (a) Asbestos: insulation workers and shipyard 
workers are exposed to asbestos. There is some increase in the risk 
of lung cancer after 10 years of exposure and a substantial risk 
after 20 years of exposure. Concurrent smoking increases the risk 
to 90 fold; (b) Arsenic : smelter workers and vineyard workers are 
exposed to arsenic. The risk is dose related. Lung cancers have an 
upper lobe predominance and there may be multiple primaries; (c) 
Nickel refinery workers : squamous cell carcinoma is more 
common; (d) Radiation (Uranium mining): oat cell carcinoma is 
more common; (e) Haematite mining: due to radon exposure; (f) 
Hard rock mining; (g) Chromium exposure in ore mining and 
pigment manufacturing: squamous cell variety is most common; (h) 
Chloromethyl exposure in workers in industries: oat cell carcinoma 
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is most common; (i) Ethers and mustard gas: squamous and 
undifferentiated carcinomas are most common; (j) Soot, tars 
exposure in coke oven workers and (k) Oils and coke exposure in 
Gas house workers, roofers and rubber workers. 
Air pollution    
 Air pollution increases the risk of lung cancer. Genetic 
susceptibility to lung cancer has long been postulated. 
Environmental agents, even cigarette smoking, cause lung cancer 
in only a minority of exposed persons, leading to the hypothesis  
that susceptibility is inherently determined.   People who eat more 
vegetables are at lower risk of lung cancer than persons who 
consume fewer vegetables. The same may also apply to fruit 
consumption, but the evidence is less clear-cut.  
Genetics 
 Recently, advanced molecular techniques have identified 
amplification of oncogenes and inactivation of tumor suppressor 
genes in NSCLC and SCLC. The most important abnormalities 
detected in NSCLC are mutations involving the ras family of 
oncogenes. The ras  oncogene family has 3 members: H-ras,  K-ras, 
and N-ras .  These genes encode a protein on the inner surface of 
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the cell membrane with GTPase activity and may be involved in 
signal transduction. To what extent these changes are causal events 
in the development of SCLC is not clearly known and remains an 
area of active research. Amplification of the myc  family of 
oncogenes is the most common molecular abnormality identified in 
SCLC cell lines, xenografts in nude mice, and fresh tumor 
specimens. This change, however, is not identified in all SCLC 
tumors. Though it is not an initial event in the pathogenesis of 
SCLC, C-myc and N-myc amplification carry a poor prognosis. 
The retinoblastoma (RB) tumor suppressor gene, is on chromosome 
13 (13q14), and a high percentage of SCLCs (as many as 60%) do 
not express RB  messenger ribonucleic acid (mRNA). This high 
frequency of inactivation of a tumor suppressor gene suggests that 
this may be an important step in the molecular pathogenesis of 
SCLC. The most common molecular abnormality, however, is 
deletion of part of chromosome 3 (3p14). Mutations of the p53  
tumor suppressor gene are found commonly in both SCLC and 
NSCLC, but their precise role in pathogenesis is not clear. 
Tobacco smoking and radon exposure are associated with p53  gene 
mutations .  
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Classification 
 Lung carcinoma is generally classified as small cell (SCLC) 
and non–small cell (NSCLC). Non–small cell lung cancer  accounts 
for approximately 75% of all lung cancers. NSCLC is divided 
further into adenocarcinoma, squamous cell carcinoma, and large 
cell carcinoma. All share similar treatment approaches and 
prognoses but have distinct histologic and clinical characteristics. 
Small cell carcinomas arise in peribronchial locations and 
infiltrate the bronchial submucosa. It exhibits aggressive behaviour 
with widespread metastases occuring early in the course of the 
disease, with common spread to mediastinal lymph nodes, liver, 
bones, adrenal glands, and brain. In addition, production of a 
variety of peptide hormones leads to a wide range of 
paraneoplastic syndromes. The most common paraneoplastic 
syndromes are the syndrome of inappropriate secretion of 
antidiuretic hormone (SIADH) and the syndrome of ectopic 
adrenocorticotropic hormone (ACTH) production. In addition, 
autoimmune phenomena may lead to various neurological 
syndromes. 
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CLINICAL FEATURES 
 Symptoms, signs relating to the lung cancer can be classified 
as follows: (1) those related to the primary lesion, (2) those related 
to intrathoracic spread, (3) those related to distant metastasis, and 
(4) those related to paraneoplastic syndromes8.   
(1)Signs and symptoms related to lung cancer:  
 Cough  is the most common presenting symptom in lung 
cancer.  Many lung cancers occur in central airways and may lead 
to postobstructive pneumonia, or cause lymph node enlargement 
that may lead to cough. Failure of acute exacerbations of COPD to 
clear should raise the suspicion of a neoplasm.  
 Dyspnoea  is usually associated with increasing cough and 
sputum. If the tumor is occluding a main airway, it can cause 
breathlessness, which may be associated with a unilateral wheeze.  
 Hemoptysis is rarely severe and usually only consists of 
blood streaking of the sputum. In patients > 40 years old with 
COPD and a smoking history presenting with hemoptysis, there 
should still be a high index of suspicion for lung cancer.  
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 Chest discomfort is often of an ill-defined nature, 
intermittent and aching in quality. Definite pleuritic pain may 
occur as a result of direct spread of the tumor to the pleural 
surface. 
(2)Signs and symptoms of intrathoracic spread:   
 Recurrent laryngeal nerve palsy  is more common in left-
sided tumors because of the circuitous route of the left recurrent 
laryngeal nerve around the aortic arch, and causes hoarseness. It is 
associated with poor expectoration with coughing, and an increased 
risk of aspiration.  
 Phrenic nerve dysfunction may be noted on the chest 
radiograph by the presence of an elevated hemidiaphragm, or can 
present with breathlessness in patients already compromised by 
lung disease.   
 Pancoast tumor is also called superior sulcus tumor, and 
arises posteriorly in the apex of an upper lobe near the brachial 
plexus,  commonly infiltrating the eighth cervical and first and 
second thoracic nerve roots. This causes pain, cutaneous 
temperature change, and muscle wasting along the relevant nerve 
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root. There is often a delay of many months before the true 
diagnosis is  revealed .  
 Horner’s syndrome  is due to involvement of the sympathetic 
chain and stellate ganglion causing unilateral enophthalmos, ptosis, 
small pupil,  and ipsilateral lack of facial sweating.  
 The chest pain  is usually dull, tends to be persistent, poorly 
localized, and unrelated to breathing or coughing. Retrosternal 
pain may be due to massive hilar and mediastinal nodal 
involvement. When chest pain is particularly severe and localized, 
it is usually related to either direct invasion of the pleura or chest 
wall by the primary tumor, or due to a rib metastasis. Tenderness 
may be elicited at the site of rib involvement and, rarely, a soft-
tissue mass can be palpated.  
 Pleural effusion ,  which may result in dyspnea, is generally 
caused by direct pleural extension, but may also be secondary to 
mediastinal node involvement and lymphatic obstruction. Signs of 
a pleural effusion include dullness to percussion and decreased 
breath sounds.  
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 Lung cancer accounts for 46 to 75% of all cases of SVC 
obstruction  (SVCO);  the most common histologic subtype 
associated with SVCO is small cell carcinoma and is due to direct 
invasion by the primary tumor, or from enlarged right paratracheal 
metastatic lymph nodes. The patient will complain of facial 
swelling, including the neck and eyelids, with dilated veins visible 
over the upper torso, shoulders, and arms. There may also be 
headache, dizziness (particularly on bending forwards), 
drowsiness, blurring of vision, cough, and dysphagia.  
 Metastases to the heart and pericardium  usually occur by 
direct lymphatic spread. At autopsy, cardiac involvement occurs in 
approximately 15% of cases, and a small number will have 
tamponade. In primary lung cancer, the pericardium is the most 
common site  of cardiac involvement.  
 Enlargement of hilar and mediastinal nodes is usually due to 
metastatic spread and seldom causes symptoms unless it is 
massive,  when it can compress the esophagus and cause dysphagia .   
(3)Symptoms and signs of extrathoracic metastasis: 
 Approximately one third of patients present with symptoms 
as a result of distant metastases. The most common sites of distant 
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metastasis from lung cancer are the bones; liver, adrenal glands,  
and intraabdominal lymph nodes; brain and spinal cord; and lymph 
nodes and skin.  
 The axial skeleton and proximal long bones  are most 
commonly involvedand the primary symptom resulting from bone 
involvement is pain.  
 Liver metastases occur commonly with lung cancer. 
However, liver function test results are seldom abnormal until the 
metastases are numerous and large. Hepatic metastases most 
commonly produce symptoms of weakness and weight loss. Hepatic 
metastases carry a very poor prognosis.  
 Adrenal lesions and para-aortic lymph node metastases may 
occur and are most commonly seen with small cell lung cancers; in 
the latter cell type, they are often discovered during staging. 
Intracranial metastases occur in 10% of patients at presentation .   
 Brain metastasis may produce headache, nausea and 
vomiting, focal neurologic symptoms or signs, seizures, confusion, 
and personality changes. The lung is the primary site of 
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approximately 70% of cancers that initially present with 
symptomatic brain metastases.  
 The most common site of palpable lymphadenopathy  is the 
supraclavicular fossa, which can be involved in 15 to 20% of cases 
during the course of the disease. Identifying an enlarged lymph 
node or subcutaneous nodule due to metastatic lung cancer is 
extremely helpful in facilitating both diagnosis and staging. Fine 
needle aspiration can be performed quickly at the bedside or as an 
outpatient with little morbidity and with a high sensitivity. 
(4)Paraneoplastic syndromes: 
 Paraneoplastic syndromes are a group of clinical disorders 
associated with malignant diseases that are not directly related to 
the physical effects of primary or metastatic tumor. The exact 
mechanism by which paraneoplastic syndromes occur is not fully 
understood. Paraneoplastic syndromes occur in at least 10% of 
patients with bronchogenic carcinoma.  
 Hypercalcemia is frequently secondary to bony metastases. It 
can, however, be due to production of a parathyroid hormone-
related peptide. It is most common with squamous cell carcinoma; 
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approximately 15% of patients acquire hypercalcemia before death. 
Symptoms include nausea, vomiting, abdominal pain, constipation,  
polyuria, thirst, dehydration, confusion, and irritability.  
 SIADH Syndrome of inappropriate Anti Diuretic hormone  
is mainly associated with small cell lung cancer, although other 
malignant tumors of the lung may rarely be associated with this 
syndrome. Manifestations of SIADH include confusion, 
unexplained seizures,  decreased level of consciousness, and coma. 
Biochemically, the syndrome is defined as low serum sodium, a 
dilute plasma osmolality with a higher, or "inappropriate" urine 
osmolality, in the presence of continued urinary sodium excretion. 
The syndrome resolves promptly (< 3 weeks) with the initiation of 
combination cytotoxic chemotherapy in 80% of patients with  
small cell lung cancer,  but commonly recurs with tumor 
progression.  Cushing syndrome-Adrenocorticotrophic 
hormone (ACTH) is the most commonly produced ectopic hormone 
in lung cancer. But Cushing syndrome is rarely seen.  Signs and 
symptoms of Cushing syndrome develop in only 1 to 5% of patients 
with small cell lung cancer. The most common features associated 
with this condition are clinical symptoms of weakness, muscle 
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wasting, drowsiness, confusion and psychosis, dependent edema, 
hypokalemic alkalosis, and hyperglycemia.  
 Digital Clubbing and Hypertrophic Osteoarthropathy may 
be associated with any cell type of lung cancer, although they are 
most frequently associated with squamous and adenocarcinoma and 
least frequently associated with small cell lung carcinoma. The 
exact mechanism for clubbing and hypertrophic osteoarthropathy is 
unknown, although suggestions include neurogenic,  hormonal, and 
vascular mechanisms. Clubbing is much more common than 
hypertrophic osteoarthropathy. Hypertrophic osteoarthropathy is 
seen in < 5% of patients with non small cell lung cancer and is 
characterized by a painful symmetrical arthropathy (usually of the 
ankles,  wrists, and knees) and periosteal new bone formation on 
the distal long bones of the limbs. 
  A variety of poorly understood neurologic syndromes may 
occur in lung cancer, and affect 4 to 5% of patients. Small cell 
carcinoma is the most common type of lung cancer associated with 
paraneoplastic autoimmune neurologic syndromes.The syndromes 
involved include Lambert-Eaton myasthenic syndrome, peripheral 
neuropathy, cortical cerebellar degeneration, and several other 
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CNS syndromes. Some of these syndromes may be identified by the 
presence of antibodies either in the serum or the cerebrospinal 
fluid.  
DIAGNOSIS 
 Once the signs and symptoms suggest the possibility of lung 
cancer,the next step is to proceed with a x-ray chest and computed 
tomography(CT) of the chest. Imaging plays an integral role in 
diagnosing, staging, and following patients with lung cancer. Most 
lung tumors are detected on chest radiographs, but unfortunately, 
the majority of patients have advanced stage disease at 
presentation. There is a wide spectrum of  radiologic 
manifestations of lung  cancer, and recognition of  these findings is 
essential for patient management.The radiographic findings and 
clinical presentation usually allow a presumptive differentiation 
between small cell lung cancer (SCLC) and non-SCLC (NSCLC). 
Massive lymphadenopathy and direct mediastinal invasion are 
well-recognized phenomena in SCLC . A mass in, or adjacent to, the 
hilum is a particular characteristic of SCLC and is seen in about 
78% of cases.  Among NSCLC,  adenocarcinoma typically 
presents as a small (often < 4 cm), peripheral, round or oval, 
smoothly marginated, solitary pulmonary nodule. 
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Bronchioloalveolar cell carcinoma (BAC) is a peculiar subtype of 
adenocarcinoma that may present with solitary or multiple lesions. 
Multifocal BAC may present as follows: (1) multiple well-defined 
nodular opacities of varying size, involving one or both  lungs 
(15%) ;  (2) focal, poorly defined opacities or multiple scattered 
opacities that may coalesce into lobar and rarely complete lung 
opacification, resembling pneumonia (10%); or (3) reticulonodular 
opacities resembling interstitial lung disease.  
 Squamous cell carcinoma  usually range in size from 1 to 10 
cm. They are typically found in the central bronchi, although one 
third occur beyond the segmental bronchi. Endobronchial neoplasm 
may result in postobstructive pneumonia and/or atelectasis in up to 
50% of cases,  and the underlying mass may be observed . Squamous 
cell carcinoma cavitates in 10 to 20% of cases, particularly in 
large peripheral lesions (30%). Cavity walls are usually thick and 
irregular, ranging in size from 0.5 to 3 cm and here it has to be 
differentiated from lung abscess. Rarely, extensive necrosis may 
result in a thin-walled cavity. Squamous cell carcinoma is the most 
common type to prove Pancoast or superior sulcus 
tumors.Asymmetry of > 8 mm in apical pleural thickening may be 
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an important finding, especially when associated with chest wall 
pain, brachial or laryngeal nerve paralysis, or bone destruction.  
 The majority of large cell carcinoma  present as a large 
(average size > 7 cm), peripheral mass, with poorly defined 
margins. Cavitation and calcification are uncommon (6%). Hilar 
and mediastinal adenopathy are seen in 30% and 10% of cases, 
respectively. Rapid growth with early lymphatic and hematogenous 
metastases occurs frequently.  
 In asymptomatic patients, a solitary pulmonary nodule may 
be an incidental finding in chest x-ray. A solitary pulmonary 
nodule (SPN) is radiologically defined as an intraparenchymal lung 
lesion that is < 3 cm in diameter and is not associated with 
atelectasis or adenopathy23. Lung lesions > 3 cm in size are defined 
as lung masses. One of 500 chest radiographs (CXRs) demonstrates 
a lung nodule. Ninety percent of these are incidental radiologic 
findings, found unexpectedly in radiographs obtained for unrelated 
diagnostic workups. The tragedy of lung cancer is directly 
associated with its delayed presentation. Signs and symptoms are 
rarely present until the malignancy has become advanced and 
possibly unresectable. Patients with the best prognosis are those 
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found to have stage IA (T1N0M0) disease. Therefore, a timely and 
accurate diagnosis of the etiology of an SPN is essential to 
providing the patient with malignancy a potential for cancer cure. 
The occult nature of a lung nodule with its few symptoms and 
inability to be detected on physical examination does not lend 
itself to the sense of immediacy prompted by the discovery of other 
potential malignancies, such as a breast mass. The differential 
diagnosis of an SPN includes neoplastic, infectious,inflammatory, 
vascular, traumatic, and congenital lesions. Other benign etiologies 
for SPNs are rheumatoid nodules, intrapulmonary lymph nodes, 
plasma cell granulomas, and sarcoidosis. Although most SPNs are 
benign,primary malignancy may be found in approximately 35% of 
SPNs, and solitary metastases can account for another 23%. 
Traditionally the presence of "benign" calcification or the absence 
of growth over a 2-year time period has been believed to be 
reliable indicators of benign disease. Benign calcification refers to 
central, diffuse, laminar, or popcorn patterns. Other types of 
calcifications such as eccentric or stippled calcifications are 
radiologically "indeterminant" and are seen in both benign and 
malignant lesions. CXRs may also falsely suggest that calcium is 
present, leading the clinician and patient to have false confidence 
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that the nodule is benign. In a recent series by Berger et al,7% of 
nodules that were believed to be "definitely calcified" by the CXR 
lacked calcium on the CT scan. Benign lesions typically have a 
doubling time of either < 1 month or > 16 months. Malignant 
nodules have a doubling time from anywhere from 40 to 360 days. 
The morphology of a nodule that is spherical with rounded edges is 
associated with benign disease.   Spiral CT with IV contrast 
enhancement is the imaging modality of choice for the SPN and 
should be obtained on all newly diagnosed SPNs. 
  Computed tomography  is now established as the best non-
invasive method for staging the lung cancer by assessing the chest 
wall invasion, pleural invasion, mediastinal invasion and 
mediastinal lymph node  
involvement. It is also useful in detecting early stage of lung 
cancer where x-ray appears normal. Radiologic studies used in 
conjunction with the International System for Staging Lung  Cancer 
include chest radiographs, CT, and occasionally MRI. The 
appropriate role of imaging in management still requires definition, 
but the major indication is to accurately differentiate stage I to 
IIIA (potentially resectable) from stage IIIB to IV (nonresectable) 
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cancer. Current imaging for bronchogenic carcinoma makes use of 
plain chest  radiographs, CT, MRI, and nuclear medicine. 
NSCLC:   Radiologic assessment of the size of primary lesions is 
usually done using plain chest radiographs and, less commonly, CT 
or MRI. CT and occasionally MRI are used to evaluate the hilar 
and mediastinal lymph nodes .  Size, unfortunately a nonspecific 
criterion, is the only criterion used in attempting to distinguish 
normal from abnormal lymph nodes (short axis > 1 cm is 
considered abnormal). Lymph node morphology and MRI signal 
characteristics are not useful in predicting lymph node 
metastases.Although CT and MRI are very accurate in 
demonstrating enlarged lymph nodes, the cause of enlargement may 
be reactive hyperplasia, not metastasis,  particularly if there is a 
postobstructive pneumonia.The accuracy of CT and MRI for 
detecting metastatic hilar (N1) disease is only 62 to 68% and 68 to 
74%, respectively20. This low accuracy of radiographic staging of 
N1 metastatic disease,  in most cases, does not prevent surgical 
resection unless the patient is a poor surgical candidate. Common 
sites of metastases are lymph nodes as described above; brain and 
CNS, bone, and adrenal gland metastases and metastases to the 
contralateral lung are considered M1 disease. Initiating a 
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radiologic investigation for metastatic disease is often based on the 
clinical history, physical examination, and blood indexes (CBC 
count, alkaline phosphatase, liver function tests).Routine 
radiologic evaluation for occult metastases in the absence of 
clinical or laboratory findings is not clearly indicated. Isolated 
CNS metastases are rare in patients with NSCLC and are generally 
associated with an abnormal neurologic examination. 
Asymptomatic brain metastases occur in 2.7 to 9.6% of patients 
usually with large cell carcinomas and adenocarcinoma. The use of 
routine CT or MRI of the CNS in asymptomatic patients with 
NSCLC is controversial. Patients with bone metastases are usually 
symptomatic (pain) or have suggestive laboratory abnormalities 
(eg ,  elevated alkaline phosphatase). Bone radiographs, 
radionuclide bone scanning with 99 technetium-methylene 
diphosphonate or MRI are useful modalities for further 
investigation. Occult skeletal metastases are rarely (up to 4%) 
detected by radionuclide 99 technetium-methylene diphosphonate 
studies,  but there is a high false-positive rate (approximately 
40%).Thus, routine radionuclide skeletal imaging should not be 
performed in NSCLC. Adrenal metastases do not produce reliable 
clinical and laboratory findings; thus, upper abdominal imaging is 
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routinely performed, especially as part of thoracic CT staging. 
Incidental nonfunctioning cortical adenomas occur in 3 to 5% of 
the population, and approximately 10% of patients with NSCLC 
will have an adrenal mass at CT.In the absence of other known 
extrathoracic metastases, an adrenal mass is more likely benign. 
Attenuation values 10 are virtually pathognomonic benign adrenal 
enlargement. CT and MRI are similar in detecting hepatic 
metastases, although isolated liver metastases are extremely 
uncommon and routine liver imaging is not usually suggested.  
 SCLC:  SCLC has been divided into two stages i.e., limited 
and extensive disease. Limited disease is defined as tumor within a 
single radiotherapy port (tumor confined to the thorax).  
 Extensive disease includes distant metastases and 
noncontiguous metastases to the contralateral lung. Long-term 
survival occurs primarily with limited disease and is rare with 
extensive disease. Extensive disease is present at presentation in 
60 to 80% of patients with SCLC. Metastases commonly occur in 
the liver (22 to 28%), bone (30 to 38%), bone marrow (17 to 25%), 
brain (8 to 15%), and retroperitoneal lymph nodes (11%). 
Abdominal CT or ultrasound should be done routinely in the 
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staging evaluation of SCLC. MRI may be more sensitive than 
contrast-enhanced CT in detecting hepatic metastases, and similar 
to CT in evaluation of adrenal metastases. Isolated bone and bone 
marrow metastases are uncommon and are usually associated with 
involvement of other organs.  
Consequently, if there are extrathoracic metastases, further 
evaluation should include a radionuclide bone scan and bone 
marrow aspiration. MRI may be more sensitive than bone 
scintigraphy in detecting small  and rapidly growing metastases 
with marrow infiltration. CNS metastases are common at 
presentation and as a site of future disease. Routine CT or MRI 
evaluation of the CNS is recommended, as approximately 5% of 
patients with cerebral metastases are asymptomatic. In NSCLC, 2.7 
to 9.6% are symptomatic and use of imaging is controversial.  
Detection and treatment with aggressive chemotherapy and 
radiotherapy can decrease morbidity and improve prognosis if the 
brain is the only site of extrathoracic disease.  
 After the radiological diagnosis and staging, the next step is 
to achieve a definitive diagnosis .     
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 Sputum cytology is the least invasive means of obtaining a 
diagnosis in a patient who is suspected of having lung cancer. The 
diagnostic accuracy of sputum cytology is dependent on rigorous 
specimen sampling (at least three specimens) and preservation 
techniques,  as well as on the location and size of the tumor (ie ,  
central  vs peripheral). Unfortunately, many institutions do not have 
an established program for sputum collection and processing, and 
therefore sputum analysis has a much lower sensitivity than that 
indicated in the data presented here (which come from institutions 
with well-established sputum analysis programs). Sputum cytology 
is particularly useful in patients who present with centrally located 
tumors (ie ,  SCLC or squamous call carcinoma) and in those who 
present with hemoptysis. 
   Flexible bronchoscopy with its attendant procedures is a 
valuable diagnostic procedure in the workup of a patient who is 
suspected of having lung cancer. The decision about whether to 
perform a diagnostic bronchoscopy for a lesion that is suspicious 
for lung cancer largely depends on the location of the lesion (ie ,  
central vs peripheral). In a patient with a central lesion, 
bronchoscopy is the most sensitive way to confirm a diagnosis of 
cancer19. Central  lesions can present as an exophytic endobronchial 
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mass, submucosal spread, or a peribronchial tumor causing 
extrinsic compression. Direct  forceps biopsy of visible central 
lesions is the technique used most frequently. At least three 
forceps biopsies of the visible lesion are recommended. The 
sensitivity from washings and brushings is somewhat lower, but 
these tests often are combined with forceps biopsies. The addition 
of Transbronchial Needle Aspiration  to obtain cytology or 
histology samples when there is submucosal tumor spread or 
peribronchial tumor causing extrinsic compression increases the 
sensitivity of bronchoscopy. Peripheral lesions are defined in most 
studies as lesions that  are not visible in the main or lobar airways, 
and thus it is not surprising that the sensitivity of flexible 
bronchoscopy for diagnosing peripheral lung cancers is lower than 
that for central lesions. A few points must be made in order to 
interpret the results of bronchoscopy in the diagnosis of  peripheral 
lung cancers. First, most of the studies used fluoroscopy routinely 
for peripheral lesions, which increases the reported sensitivity of 
bronchoscopy. In a patient with a small (ie , < 2 cm) peripheral 
lesion, the sensitivity of bronchoscopy is low. The false-negative 
(FN) rate for bronchoscopy results has not yet been defined. Most 
clinicians would pursue the diagnosis further in the case of a 
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nondiagnostic bronchoscopy of a visible endobronchial 
abnormality. The FN rate can be estimated to be fairly high in the 
case of peripheral lesions, especially smaller ones, because of the 
relative low sensitivity in this setting. Bronchoscopy has an 
important role in the diagnosis of benign conditions, but the chance 
of finding a benign condition in a patient who is clinically 
suspected of having lung cancer is only 1%.   
Percutaneous transthoracic needle aspiration (TTNA) biopsy  is a 
commonly used diagnostic procedure when a lung tumor is 
diagnosed. It is generally regarded as a safe procedure with limited 
morbidity and extremely rare mortality. The most common 
complication is a pneumothorax that will occasionally require a 
chest tube. Since TTNA is highly sensitive for diagnosing 
malignancy,1 a diagnosis of malignancy obtained by TTNA can be 
regarded as having a high predictive value and the patient should 
be treated accordingly. In some cases, however, the results from 
TTNA can be nonspecific.  Since many patients are not surgical 
candidates, TTNA is a necessary procedure to obtain a tissue 
diagnosis before starting radiation therapy or chemotherapy. In 
patients with a solitary pulmonary nodule, one could calculate the 
probability of malignancy as described by Cummings et al.18 
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Cummings and coauthors18 used Bayes’ theorem to develop a 
simple method for combining individual clinical features of 
patients with solitary pulmonary nodules (specifically the size of 
the nodule, the patient’s age and smoking history, and the clinical 
setting in which the nodule was discovered) into an overall 
estimate of the probability that the nodule is malignant. For 
patients who have a low probability of malignancy, TTNA is 
probably not the most ideal diagnostic method since it has a low 
sensitivity for benign tumors. Surgery would not be the best choice 
either since there would be an increased likelihood of 
unnecessarily operating on a benign lesion. Instead, core biopsy 
could be utilized in these patients since it has been shown to be 
very effective at diagnosing benign lesions. This technique may be 
more likely to produce a pneumothorax, but it will avoid the need 
for a surgical procedure. Conversely, if a patient has a pulmonary 
tumor with a high likelihood of being malignant, and that patient is 
a surgical candidate, then immediate surgery is most likely to be 
the optimum treatment method. If this hypothetical patient 
underwent TTNA and this resulted in a nonspecific diagnosis, then 
the patient would prob-ably be referred for open surgical biopsy. If 
this same patient underwent TTNA and was diagnosed as having a 
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malignancy, then the eventual treatment would still be surgical 
resection. For patients such as this, TTNA adds risk and cost but 
does not change the treatment plan for the patient. TTNA is most 
useful for diagnosing pulmonary nodules that are highly likely to 
be malignant in patients who are not candidates for other surgical 
procedures.  
Lymph node biopsy:  Tissue sampling from obvious metastatic 
sites is yet another way by which the diagnosis of lung cancer can 
be established. 
 If a diagnosis is not well established y any of the above 
procedures a thoracotomy may be necessary, however this decision 
is not taken lightly and the general guideline is the procedure 
undertaken only when a potential cure from lung cancer can be 
anticipated. 
STAGING 
  The stages represent the nature and extent of spread of a 
neoplasm and, thus, the therapeutic options and prognosis in 
individual patients. Stages also provide a standard by which 
various therapies can be compared. A combination of clinical, 
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laboratory, radiologic, and pathologic investigations are used to 
stage various neoplasms.  
 Different staging systems have been developed. The most 
widely used scheme for staging NSCLC is the TNM classification. 
The UICC and the AJCC initially introduced this system in 1972 
with staging and end-results reporting. This scheme has been 
modified and refined over the years. The TNM classification in the 
publications of the UICC and the AJCC are identical. They were 
formulated together but appear in separate books—namely, the 
UICC TNM Classification of Malignant Tumors  and the AJCC 
Cancer Staging Manual. Both are in their sixth editions and were 
published in 2002.  
 TNM is a dual system with a pretreatment Clinical 
classification (cTNM or TNM) and a postsurgical histopathologic 
Pathological classification (pTNM6). Both classifications are 
retained unaltered in the patient's record. The former is used for 
the choice of treatment; the latter is used for the estimation of 
prognosis and the possible selection of adjuvant therapy.  
 The TNM staging system takes into account the degree of 
spread of the primary tumor, represented by T; the extent of 
 37
regional lymph node involvement, represented by N; and the 
presence or absence of distant metastases, represented by M. The 
TNM system is used for all lung carcinomas except SCLCs, which 
are staged separately.  
 In the TNM systems, 4 stages are further subdivided into I-
III and A or B subtypes. These stages have important therapeutic 
and prognostic implications. The stages are as follows. 
Primary tumor  
Tis - Carcinoma in situ  
TX -  Positive malignant cytologic findings, no lesion observed  
T1 - Diameter of 3 cm or smaller and surrounded by lung or 
visceral pleura or endobronchial tumor distal to the lobar bronchus  
T2  -Diameter greater than 3 cm; extension to the visceral pleura, 
atelectasis, or obstructive pneumopathy involving less than 1 lung; 
lobar endobronchial tumor; or tumor of a main bronchus more than 
2 cm from the carina  
T3  - Tumor at the apex ; total atelectasis of 1 lung; endobronchial 
tumor of main bronchus within 2 cm of the carina but not invading 
it; or tumor of any size with direct extension to the adjacent 
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structures such as the chest wall mediastinal pleura, diaphragm, 
pericardium parietal layer, or mediastinal fat of the phrenic nerve  
T4 - Invasion of the mediastinal organs, including the esophagus 
trachea, carina, great vessels, and/or heart; obstruction of the 
superior vena cava; involvement of a vertebral body; recurrent 
nerve involvement; malignant pleural or pericardial effusion; or 
satellite pulmonary nodules within the same lobe as the primary 
tumor. 
Regional lymph node involvement  
N0 - No lymph nodes involved  
N1 -  Ipsilateral bronchopulmonary or hilar nodes involved  
N2 -  Ipsilateral mediastinal nodes or ligament involved  
Upper paratracheal lower paratracheal nodes  
Pretracheal and retrotracheal nodes 
Aortic and aortic window nodes 
Para-aortic nodes 
Para-esophageal nodes 
Pulmonary ligament 
Subcarinal nodes 
N3  - contralateral mediastinal or hilar nodes involved or any 
scalene or supraclavicular nodes involved. 
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Metastatic involvement  
M0 - No metastases  
M1 - Metastases present 
Stage groupings are as follows:  
IA - T1N0M0  
IB  - T2N0M0  
IIA - T1N1M0  
IIB -  T2N1M0 or T3N0M0  
IIIA  - T1-3N2M0 or T3N1M0  
IIIB  - Any T4 or any N3M0  
IV  - Any M1 
Staging of SCLC 
 SCLC has usually metastasized by the time of presentation. 
Extensive disease is present in more than 60% of patients. Surgery 
is an option in fewer than 5% of these patients, who have a small 
primary and no evidence of spread. Systemic chemotherapy is the 
main treatment, with response rates of 70% but cure rates of less 
than 5%.  
 The distinction between limited and extensive disease is an 
important staging issue. The TNM system may be applied, but it is 
not directly relevant to management decisions. The objectives of 
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staging in SCLC are to identify localized disease, for which 
radiation therapy may be suitable, and to quantify the extent of the 
disease before therapy.  
 Localized disease is defined as disease confined to 1 
hemithorax that includes ipsilateral, contralateral, and/or 
supraclavicular nodes. Investigations include chest radiography; 
CT of the thorax, liver, and adrenal glands; cranial CT; bone 
scintigraphy; and bone marrow aspiration. The disseminated nature 
of SCLC makes whole-body survey techniques suitable for its 
evaluation. 99mTc-labeled monoclonal antibody fragment NR-LU-
10 is used to detect an antigen present in most small cell cancers.  
 Pulmonary Function Testing 
 Many patients with NSCLC have moderate to severe chronic 
lung disease that increases the risk of perioperative complications 
as well as long-term pulmonary insufficiency following lung 
resection. All patients considered for surgery require spirometry. 
In the absence of other comorbidities, patients with good lung 
function (preoperative FEV1 > 2 L) are at low risk for 
complications from lobectomy or pneumonectomy. 
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Screening 
 The optimal screening of smokers for lung cancer is unclear. 
Both chest radiographs and analysis of expectorated sputum is 
ineffective. Recent studies have tried to assess the role of chest CT 
scans. A study by Bach et al showed that CT screening of 
populations increases the diagnosis of lung cancer but does not 
reduce the risk of advanced lung cancer or reduce mortality. The 
investigators of the International Early Lung Cancer Action 
Program, however, suggested that there is a role for screening with 
chest CT. These studies highlight how complex and confusing the 
analysis of screening for lung cancer can be. At the present time, 
there are inadequate data to recommend the use of chest CT to 
screen smokers for lung cancer. The National Lung Screening Trial 
is an ongoing large, multicenter study that should answer the 
question definitively.  
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MANAGEMENT OF LUNG CANCER 
Non–small cell carcinoma 
Cure of NSCLC is unlikely without resection. Clinical features 
that preclude complete resection include extrathoracic metastases 
or a malignant pleural effusion; or tumor involving the heart, 
pericardium, great vessels, esophagus, recurrent laryngeal or 
phrenic nerves, trachea, main carina, or contralateral mediastinal 
lymph nodes.  
 Accordingly, stage I and stage II patients are treated with 
surgical resection where possible, and stage II are additionally 
recommended to receive adjuvant chemotherapy46.  
 Stage IIIA patients have poor outcomes when treated with 
resection alone. They should be referred to multimodality 
protocols, including chemotherapy and radiotherapy.  
 Stage IIIB patients treated with combined chemotherapy and 
radiation therapy have improved survival. Selected stage IIIB 
patients taken to resection following multimodality therapy have 
shown long-term survival and may be cured.  
 Stage IV patients are treated with symptom-based palliative 
therapy, which may include outpatient chemotherapy. Neoadjuvant 
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chemotherapy consists of giving antineoplastic drugs in advance of 
surgery or radiation therapy.  
 There is no consensus on the impact of neoadjuvant therapy 
on survival in stage I and stage II NSCLC. Such therapy is not 
recommended outside of ongoing clinical trials. Neoadjuvant 
therapy is more widely used in selected patients with stage IIIA or 
stage IIIB disease. Some studies suggest a survival advantage. This 
remains an area of active research. Adjuvant chemotherapy 
consists of administering antineoplastic drugs following surgery or 
radiation therapy. Adjuvant chemotherapy with alkylating agents 
such as cyclophosphamide increases mortality. In stage I and N0 
stage II disease, patients treated with multidrug platinum-based 
chemotherapy show a trend toward improved survival—on the 
order of 3 months at 5 years. Toxicity may be significant, 
however, and such therapy is not routine. Newer antineoplastic 
agents with less toxicity are in clinical trials in these patients, and 
gene expression profiling has shown promise in defining a subset 
of patients with stage IA disease who may benefit. In patients with 
stage IIIA disease and node positive stage II disease, the data are 
conflicting whether chemotherapy following surgery improves 
survival. Patients with locally advanced disease (stages IIIA and 
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IIIB) who are not surgical candidates have improved survival when 
treated with combination chemotherapy and radiation therapy 
compared with no therapy or radiation alone. 
Small cell carcinoma 
Response rates of SCLC to cisplatin and etoposide are excellent: 
80–100% response in limited-stage disease (50–70% complete 
response), and 60–80% response in extensive stage disease (15–
40% complete response). However, remissions tend to be short-
lived with a median duration of 6–8 months. Once the disease has 
recurred, median survival is 3–4 months. Overall 2-year survival is 
20% in limited-stage disease and 5% in extensive-stage disease. 
Thoracic radiation therapy improves survival in patients with 
limited SCLC but not those with extensive disease. Whole brain 
radiation therapy decreases the incidence of central nervous 
system disease but does not affect survival. Its effect on symptoms 
is controversial. 
 Occasionally, a patient may have a peripheral nodule 
resected that turns out to be SCLC. Five-year survival following 
resection of the equivalent of stage I and stage II SCLC is higher 
than in patients treated with chemotherapy. 
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Palliative therapy 
 Photoresection with the Nd:YAG laser is sometimes 
performed on central tumors to relieve endobronchial obstruction, 
improve dyspnea, and control hemoptysis. External beam radiation 
therapy is also used to control dyspnea and hemoptysis, pain from 
bony metastases, obstruction from superior vena cava syndrome, 
and symptomatic brain metastases. Resection of solitary  brain 
metastases does not affect survival but may improve quality of life 
when combined with radiation therapy. Intraluminal radiation 
(brachytherapy) is an alternative approach to endobronchial 
disease. Pain syndromes are very common in advanced disease. As 
patients approach the end of life, meticulous efforts at pain control 
are essential. Consultation with or referral to a palliative care 
specialist is recommended in advanced disease to aid in symptom 
management and to facilitate referrals to hospice programs. 
Prognosis 
The overall 5-year survival rate for lung cancer is 15%. 
Predictors of survival are the type of tumor (SCLC versus 
NSCLC), the stage of the tumor, and the patient's performance 
status, including weight loss in the past 6 months. These are 
independent predictors in both early and late stage disease. Most 
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data suggest that there is no difference among non–small cell 
carcinomas when adjusted for stage and performance status. 
However, squamous cell carcinoma may have a better prognosis 
than adenocarcinoma or large cell carcinoma at the same TNM 
stage. 
 Since lung cancer carries the highest mortality among all 
cancers, and no treatment carries a best prognosis, prevention of 
lung cancer through reduction of tobacco use is the primary 
stratergy that will result in marvelous reduction in lung cancer 
incidence. 
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MATERIALS AND METHODS 
 The study was conducted in Government Rajaji Hospital,  
Madurai. Lung cancer patients from various departments such as 
Medical oncology, General medicine, Thoracic medicine and 
Cardiothoracic surgery wards were proposed to collected for study. 
Ethical committee approval was  obtained for the study.  
TYPE OF STUDY – PROSPECTIVE STUDY  
 
Inclusion criteria 
 
 All the patients admitted with clinical picture and Imaging 
suggestive of lung cancer, and later proved to be of primary lung 
malignancy were included in the study. 
 
Exclusion criteria 
 
 Multiple mass lesion lung suggestive of secondaries but 
without evidence of primary lung mass. 
 
 Multiple mass lesion lung with hilar mass but without any 
evidence of growth by bonchoscopy. 
 
 Mass lesion lung suggestive of primary lung cancer but 
biopsy not confirmed. 
 48
 The study was conducted during the period between July 
2006 and June 2007. Totally fifty newly diagnosed lung cancer 
patients were collected for the study. The main inclusion criteria 
for the study were patients with histological evidence of lung 
cancer in those with mass lesion lung. Mass lesion lung patients in 
whom histological evidence could not be made because of the non 
consent by patients were excluded from the study.  
 Elaborative clinical data were collected from these patients. 
They include age, sex, presenting complaints cough, chest pain, 
dyspnoea, hemoptysis, hoarseness of voice, neural pain along ulnar 
border, facial puffiness, dysphagia, fever, bone pain, weakness, 
neck swelling, headache, seizures, focal neurological deicits, bony 
and skin swellings. Smoking history was collected that revealed 
whether they smoked cigarette, beedi or both, number of 
cigarettes/beedis smoked per day, number of years of smoking and 
h/o passive smoking. Past history of pulmonary tuberculosis and 
Family history of lung cancer and other cancers were also probed 
through. All patients were examined for clubbing, e/o 
lymphadenopathy, e/o paraneoplastic syndromes, e/o consolidation, 
collapse and pleural effusion. Also the patients were subjected for 
examination of hepatomegaly with nodules, cutaneous and bony 
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swellings, papilloedema, focal neurological deficits to identify 
metastasis.  
 All patients were taken x-ray chest postero anterior view. 
and they were looked for mass lesion lung and its location, 
mediastinal widening, pleural effusion, rib infiltraion, multiple 
lung secondaries. For confirmation and staging purpose they were 
all done a computed tomography of chest and noted for mass lesion 
lung and its location, mediastinal nodes, mediastinal invasion, 
pericardial effusion and invasion, pleural effusion, pleural 
invasion and nodules, chest wall infiltraion, multiple lung 
secondaries. For the same they were all subjected to ultrasonogram 
abdomen to study for abdominal secondaries.For those patients 
whom had symptoms and signs of central nervous system were 
subjected for computed tomography brain for proof of secondaries. 
Only two patients whom had bony symptoms did a bony 
scitigraphy done outside our hospital. They came here with those 
results and consulted us for the first time.  
 And only thirty patients consented for bronchoscopy and they 
were examined for bronchial growth, carina widening, tracheal 
invasion and vocal cord palsy by our thoracic physicians. They 
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also underwent biopsy of the growth and bronchoalveolar lavage 
was done in those patients and sent for histopathological study. In 
other patients, with their written consent, tissue for 
histopathological proof was attempted with CT guided trucut 
biopsy done by radiologist, supraclavicular node biopsy done by 
surgeons and the tissue was sent for the histopathological 
investigation.   
 Based on all above mentioned clinical features and 
investigation staging was done.  
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RESULTS 
 Out of 89 patients who were admitted for suspected lung 
cancer only fifty patients consented for imaging and procedures 
and they were included for study. The remaining 39 patients were 
excluded from the study because of 1) their denial for imaging due 
to financial constraints, 2)their denial for invasive procedures due 
to their illiteracy leading to fear, 3)their denial for prolonged 
hospital stay since some of the patients had come from a long 
distance for tertiary care.  
AGE AND SEX   
TABLE 1: SEX DISTRIBUTION 
 
Sex No: of patients(n) 
(Total-50) 
In percentage (%) 
Male 44 88% 
Female 6 12% 
Male: Female ratio 
7.33:1 
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TABLE 2: AGE DISTRIBUTION 
 
Age Range(In 
years) 
No: of patients(n) 
(Total-50) In percentage(%) 
<40 7 14% 
41-60 36 72% 
>60 7 14% 
Mean age 51.7 years 
 Out of 50 pts 44 were male and 6 were female the ratio came 
as 7.3:1. The mean age of presentation was 51.7 years. Smoker to 
non-smoker ratio is 3.54: 1.  
SMOKING PATTERN 
TABLE 3: SMOKER VERSUS NON SMOKER DISTRIBUTION 
 
Smoking status No: of patients(n) 
(Total-50) 
In percentage(%) 
Smokers 39 78% 
Non smokers 11 22% 
Smoker : Non smoker ratio 
3.54:1 
Almost all the smokers were beedi smokers. Many were 
smoking both beedi and cigarette. Only very few smoked only 
cigarettes among smokers. More than half of non smokers were 
passive smokers.   
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COMORBID CONDITIONS  
 2 patients had significant past history of pulmonary 
tuberculosis before 10 years. 4 patients had recent history of 
pulmonary tuberculosis within a year and was put on 
antituberculosis treatment. One patient gave history of chronic 
obstructive pulmonary disease. Two patients gave history of other 
than lung cancers in their family. But none had family history of 
lung cancer.  
SYMPTOMS AND SIGNS 
TABLE 4: CLINICAL FEATURES RELATED TO PRIMARY LUNG 
CANCER 
 
F/o primary lung No: of patients(n) (Total-50) 
In percentage(%) 
Cough 37 74% 
Dyspnoea 21 42% 
Hemoptysis 14 28% 
Chest pain 32 64% 
E/o collapse 6 12% 
E/o consolidation 4 8% 
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TABLE 5: CLINICAL FEATURES RELATED TO INTRATHOTACIC 
SPREAD 
 
F/o intrathoracic spread No: of patients(n) (Total-50) 
In percentage(%) 
Rec. laryngeal n palsy 14 28% 
Pleural effusion 8 16% 
SVC obstruction 5 10% 
Oesophagus 6 12% 
 
 
 
TABLE 6: CLINICAL FEATURES RELATED TO EXTRATHORACIC 
SPREAD 
 
F/o extrathoracic spread No: of patients(n) (Total-50) 
In percentage(%) 
Bone pain 8 16% 
Brain metastasis 8 16% 
Lymph node 13 26% 
Cutaneous secondaries 2 4% 
 Among the symptoms of primary lung,the predominant 
symptom cough was present in 37 patients. Dyspnoea was present 
in 21 patients, hemoptysis in 14 patients, chest pain in 32 patients.  
 Among the clinical features related to intrathoracic spread, 
hoarseness of voice was present in 14 patients, features of 
pancoast tumour in 6 patients and among them horner’s syndrome 
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in 3, then evidence of pleural effusion in 8, facial puffiness due to 
SVC obstruction in 5, dyspahagia due to oesophageal involvement 
in 6. 
 Among the clinical features related to extrathoracic spread, 
bone pain was present in 8 patients, liver secondaries in 5, 
evidence of CNS metastasis headache, seizures, papilloedema and 
focal neurological deficits were found in 8 patients, 
supraclavicular lymphadenopathy in 13, skin secondaries in 2. 
 Regarding features of paraneoplastic syndrome, 28 patients 
had clubbing of various grading among whom one had grade IV 
clubbing that was hypertrophic pulmonary osteoarthropathy.   
 Among the other clinical features, weight loss found in 29 
patients, weakness in 16, fever in 11, other features like edema 
hand, chest wall mass in 11 patients. 
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IMAGING 
TABLE 7: FINDINGS IN CT CHEST 
 
CT chest findings No: of patients(n) (Total-50) In percentage(%) 
Mass lesion 50 100% 
Pleural involvement 20 40% 
Mediastinal involvement 17 34% 
Chest wall invasion 15 30% 
Lung secondaries 7 14% 
Phrenic nerve palsy 3 6% 
 
TABLE 8: LOBAR DISTRIBUTION AS PER CT CHEST 
 
Lobar distribution as per 
CT chest 
No: of patients(n) 
(Total-50) In percentage(%) 
Right upper lobe 21 42% 
Right middle lobe 5 10% 
Right lower lobe 5 10% 
Left upper lobe 17 34% 
Left lower lobe 2 4% 
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TABLE 9: FINDINGS IN ULTRASOUND ABDOMEN 
 
Ultrasound abdomen No: of patients(n) 
(Total-50) 
In percentage(%) 
Normal 44 88% 
Liver secondaries 5 10% 
Adrenal secondaries 3 6% 
Renal secondaries 1 2% 
Para aortic lymph node 
sec 
2 4% 
 
 All 50 patients had findings suggestive of malignancy in 
chest x-ray. The findings of computerized tomography were as 
follows, 1) All patients show mass lesion suggestive of malignancy 
and they were sorted out on the basis of site of lobe involvement 
2) Pleural involvement found in 20 patients 3) Chest wall invasion 
found in 15 patients 4) Mediastinal involvement found in 17 
patients 5) Elevated diaphragm suggestive of phrenic nerve palsy 
found in three patients 6) Lung secondaries from primary lung 
found in 7 patients. Regarding lobar involvement right upper lobe 
showed mass in 21 patients, right middle lobe in 5 patients, right  
lower lobe in 5 patients, left upper lobe in 17 patients and left 
lower lobe in two patients. CT brain was taken in six patients who 
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had clinical features of brain involvement and all showed brain 
metastases.   
 Ultrasonogram abdomen done in all patients and among them 
5 showed liver secondaries, 3 showed adrenal secondaries, one 
showed renal secondaries and 2 showed paraaortic adenopathy.  
BRONCHOSCOPY 
TABLE 10: BRONCHOSCOPIC FINDINGS 
 
Bronchoscopic 
findings No: of patients(n) In percentage (%) 
Done in 30 60% 
Normal 12/30 40% 
Endobronchial Growth 16/30 54% 
Vocal cord palsy 9/30 30% 
Carina widening 4/30 13% 
Tracheal invasion 1/30 3% 
 
 Fibreoptic  bronchoscopy was done in 30 patients. In them 16 
showed bronchial growth, 9 had vocal cord palsy, 4 had carinal 
widening, one had tracheal invasion and normal in 12 patients.  
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TYPE OF LUNG CANCER 
TABLE 11: CLASSIFICATION OF LUNG CANCER 
 
 
Histopathology 
No: of 
patients(n) 
In 
percentage(%) 
Squamous cell 13 26% 
Adeno 
carcinoma 12 24% 
Large cell 
carcinoma 7 14% 
Small cell 
carcinoma 4 8% 
Others 16 32% 
 
 
 Histopathological evidence proved squamous cell carcinoma 
in 13 patients, adenocarcinoma in 12 patients, large cell carcinoma 
in seven patients, small cell carcinoma in 4 patients and carcinoma 
unspecified was repoted in 8 patients. And the remaining 6 had 
bronchoalveolar lavage examination suggestive of malignancy.  
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STAGING 
TABLE 12: STAGING OF NON SMALL CELL LUNG CANCER 
 
Stage of lung cancer No: of patients(n) In percentage (%) 
I 2/46 4% 
II 1/46 2% 
IIIa 7/46 15% 
IIIb 17/46 37% 
IV 19/46 41% 
Total no: of non small cell lung carcinoma patients- 46/50 
 
TABLE 13: DISTRIBUTION OF STAGING OF SMALL CELL LUNG 
CANCER 
 
Stage of lung cancer No: of patients(n) In percentage (%) 
Limited stage 0/4 0% 
Extensive stage 4/4 100% 
Total no: of small cell lung cancer patients- 4/50 
 Based on the above findings staging was attempted in all 
patients. Among patients proved as non small cell carcinoma, 
carcinoma unspecified and bronchoalveolar lavage showing 
malignant cells two patients were in stage I, one in stage II, 7 in 
stage IIIa, 17 patients in stage IIIb, 19 in stage IV. Among patients 
proved as small cell carcinoma all 4 had extensive disease. 
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DISCUSSION 
AGE AND SEX DISTRIBUTION  
 From 50 patients with newly diagnosed lung cancer, the 
mean age of presentation is 51.7 years compared to 54.6 years in 
the previous Indian study series8 that showed that majority had 
clinical presentation in comparatively younger age. Young 
carcinoma patients (<40 yrs) constituted 14% compared to 12.5% 
in a madras study11. Sex ratio is 7.33:1 in this study compared to 
5.76:1 that is an average of large series of Indian study. This 
implies a slightly decreased incidence in female but comparable to 
madras study that showed 7.9:111. 
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TABLE 14: COMPARISON OF DEMOGRAPHIC PATTERN IN 
LUNG CANCER 
 
1958-1985 
Indian study 
series 
1986-2001 
Indian study 
series 
GRH study 
Male:Female 6.67:1 5.76:1 7.33: 1 
Mean age (yrs) 52.16 54.6 51.7 
Smoker/NonSmoker 
ratio 
2.7:1 3-20:1 3.54:1 
 
SMOKING PATTERN AND DISTRIBUTION   
 Smokers to non smokers’ ratio found to be 3.54: 1 that was 
comparable to average of Indian study series that showed ratio 
ranging between 3-20:18.  
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SYMPTOMS AND SIGNS ANALYSIS 
TABLE: 15- COMPARISONS OF CLINICAL FEATURES OF 
PRIMARY LUNG  CANCER 
F/o primary lung 
American and 
European study 
series15 
GRH study 
Cough 8-75% 74% 
Dyspnoea 3-60% 42% 
Hemoptysis 6-35% 28% 
Chest pain 20-49% 64% 
 Cough was the predominant symptom involved as reported in 
almost all studies. Followed by chest pain was the next 
predominant symptom that shows this presentation varies from 
western study. Probably the reason could be that Indian patients 
present here in advanced stage explaining the pleural and chest 
wall infiltration. And other symptoms hemoptysis and dyspnoea 
were comparable to their range.    
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TABLE 16: COMPARISON OF FEATURES OF INTRATHORACIC 
SPREAD 
F/o intrathoracic spread 
American and 
European study 
series15 
GRH study 
Rec. laryngeal n palsy 2-18% 28% 
Pleural effusion 8-15% 16% 
SVC obstruction 0-4% 10% 
Oesophagus 0-2% 12% 
All clinical features for intrathoracic spread at presentation 
here were found to be beyond the range of western study and 
probably the reason here again was their presentation at an 
advanced stage.  
TABLE 17: COMPARISON OF FEATURES OF 
EXTRATHORACIC SPREAD 
F/o extrathoracic spread 
American and 
European study 
series15 
GRH study 
Bone pain 25% 16% 
Brain mets 10% 16% 
Lymph node 15-20% 26% 
Cutaneous secondaries 1-12% 4% 
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 Here the clinical features of brain metastasis and lymph node 
metastasis were higher in GRH study compared to western study. 
And bone pain and cutaneous were within the reference range.  
COMORBID CONDITIONS 
 Only two patients had significant past history of tuberculois 
with radiological evidence. But the reports about association of 
tuberculosis and lung cancer were conflicting29. So here it is not 
dealt with detail. Two patients were reported with family history 
of other cancers and but again the reports say that the associations 
were also conflicting.  
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IMAGING 
TABLE 18: COMPARISON OF DISTRIBUTION OF SITE OF 
LUNG CANCER 
 
 All patients had mass in chest x ray compared to Sharma et 
al26 study that showed 96% mass lesion lung. Upper zone mass 
were found in 62% of patients compared to only 42% in his study. 
The predominance of upper lobe lesion is associated with smoking 
as the risk factor for lung cancer. 
 
TABLE 19: COMPARISON OF SIDE OF LUNG CANCER 
 N.A.Khan et al10 GRH study 
Right lung 63% 62% 
Left lung 37% 38% 
 
 
Zonal distribution C.P.sharma et al26 GRH study 
Upper zone 42% 62% 
Middle zone 32% 20% 
Lower zone 16% 14% 
Entire lung 8.8% 4% 
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 The predominance of right lung involvement compared to left 
lung here was similar to N.A.Khan et al10 study.  
 Other findings in CT such as pleural involvement was found 
in 28% of patients compared to 25% as showed by Behera et al8. 
Other features chest wall invasion and mediastinal involvement 
show the increased presentation at an advanced stage again.  
 All patients with clinical features of brain metastasis showed 
evidence of metastasis in CT brain. But as a part all patients with 
small cell carcinoma could not be subjected for CT brain as a 
routine because of poor compliance of the patient to spend due to 
financial constraints.  
 Again no patients were willing for CT abdomen as a routine 
procedure for staging in addition to CT chest due to the above said 
reason. And so they were all done ultrasonogram abdomen, looking 
for the evidence of liver,adrenal metastasis. Comparitively 
ultrasound is less sensitive to CT abdomen in detecting liver and 
adrenal metastasis unless otherwise the metastatic mass is large 
enough. So only 5 patients showed liver metastasis, 3 patients 
showed adrenal metastasis and one showed renal metastasis.   
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BRONCHOSCOPY 
 Out of 50 patients only 30 patients underwent bronchoscopy. 
Among them 53% showed bronchial growth compared to Zavala et 
al study that showed bronchial growth in 58%.  
 
CLASSIFICATION OF LUNG CANCER  
 
 
TABLE 20: COMPARISON OF TYPE OF LUNG CANCER BASED ON 
PATHOLOGY  
 
 
Classification 
 
Yang et al  Arora et al GRH study 
Squamous cell 
 
23% 27% 26% 
Adeno 
carcinoma 
 
45% 21% 24% 
Large cell 
carcinoma 
 
35 13% 14% 
Small cell 
carcinoma 
 
11% 1% 8% 
Carcinoma 
unclassified  
 
16% 38% 32% 
 
 Non small cell carcinoma patients constituted about 64% and 
patients with small cell carcinoma constituted about 8%. 
Carcinoma unspecified constituted about 16%. Though the western 
studies show non small cell carcinoma accounts for 80% of lung 
cancer and small cell carcinoma accounts for 20% , the same did 
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not match with variable Indian studies including the GRH study.  
The reason could be multiple diagnostic techniques are needed to 
show a positive diagnostic yield in 70-90% of lung cancer patients. 
Here it was very difficult to subject the patients for multiple 
invasive procedures. The reason was they disagree for such 
procedures and it remained difficult to make them understand the 
pros and cons amidst of their ignorance and illiteracy. One another 
reason for underreporting of small cell carcinoma could be 
explained, was that the patients were brought with a rapid course 
of lung disease and they came here at an end stage. Before a 
complete evaluation the patients were becoming critically ill and 
no more investigations could be made. This sort of scenario with 
radiological evidence of lung cancer with rapid deterioration 
supports the probability of small cell lung cancer.  
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STAGING  
 
TABLE 21  : COMPARISON OF STAGE OF NSCLC 
 
Stage of lung cancer Yang et al (Mayo clinic) In percentage (%) 
I 26% 4% 
II 8% 2% 
III 31% 52% 
IV 35% 41% 
 
 
TABLE 22  : COMPARISON OF STAGE OF SCLC 
 
Stage of lung cancer Yang at al ( Mayo clinic) GRH study 
Limited stage 47% 0% 
Extensive stage 53% 100% 
 
 
 72% of non small cell lung carcinoma patients were in Stage 
IIIb and IV. All 4 patients with small cell carcinoma were in 
extensive stage. This shows that most patients presented only in an 
advanced stage. Though surgery is the only treatment with 
potential for cure, there is a significant delay before patients 
finally present; consequently, most patients have advanced stage 
disease where surgery is not possible.  
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 One of the limitations in this study was that staging 
procedures were done only to limited extent in all patients. In spite 
of it the majority showed an advanced stage.  
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CONCLUSION & SUMMARY  
 
 Majority of the patients here were males and majority of 
them were smokers, approximately 78%. There is very less 
awareness about hazards of smoking and this area should be highly 
given prior importance because in lung cancer prevention is far 
better than cure.  
 
 Young patients with lung cancer, age<40 years were also in 
higher proportion in regard to western population and all patients 
present at an earlier age compared to western population. These 
indicate the probability of air pollution contributing to lung cancer 
in addition to smoking. This should be taken into serious 
consideration and the policies regarding pollution control should 
be made to follow strictly. 
 
 Next to cough (72%), chest pain (64%) was the most common 
symptom. The general practitioners should be made aware of such 
symptoms and they should start evaluating the susceptible patients 
early for lung cancer. This would help the patient to detect lung 
cancer at an early stage. They should also be retrained regularly 
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regarding chest x ray interpretation. This could avoid possible 
confusion in treating the lung cancer patients as pulmonary 
tuberculosis based on imaging alone. 
 Again imaging also supported the increased smoking hazard, 
by showing an increased upper lobe site for lung cancer in approx. 
62% of patients.  
 
 All patients were subjected only to CT thorax and 
ultrasonogram abdomen, and few patients did CT brain as 
indicated. Bronchoscopy was done in 30 out of 50 patients. The 
importance of complete evaluation of a lung cancer patient should 
be emphasized upon, including imaging apart from CT thorax, 
bronchoscopy and invasive procedures for a pathological proof and 
staging. Because this would help the patient to stage his/her 
disease perfect, so that he/she will be benefited by appropriate 
treatment.  
 
 Coming to staging majority, approx. 80% presented here in 
an advanced stage. This again supports the lack of awareness 
among public about the deadly disease and low index of suspicion 
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among general practitioners. As already said this should be 
focused upon to detect early lung cancer. 
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PROFORMA  
 
NAME       AGE    SEX   
 
OCCUPATION     ADDRESS     
 
CLINICAL HISTORY: 
                                   
 
 
 
  
 
Cough    
Weight loss   
Dyspnoea    
Chest pain   
Hemoptysis    
Bone pain   
Fever    
Weakness   
Facial puffiness   
Dysphagia    
Wheeze    
Neck swelling   
Neural pain,paresthesia   
Hoarseness of voice   
Others  
 
Smoking:  No:of cigaratte/beedi/cherrut 
  
                 No:of years  
  
                Passive smoking  
 
 
Past history:  PT 
 COPD 
                      Diabetes mellitus 
                      Hypertension 
                      IHD 
 
Family history:  
  
GENERAL EXAMINATION 
Facial puffiness  
Clubbing   
Hypertrophic pulmonary osteoarthropathy  
Lymph nodes  
 Rt  Lt  
Cervical    
Scalene    
Supraclavicular    
Others  
 
 
Edema  
Gynaecomastia   
Others:  
 
 
 
 
RESPIRATORY SYSTEM EXAMINATION 
 
 
 
OTHER SYSTEMS 
 
CARDIOVASCULAR SYSTEM: 
 
ABDOMINAL EXAMN: E/o hepatic secondaries 
 
 
NERVOUS SYSTEM: E/o brain secondaries 
     E/o spinal cord compression 
      
 
OTHER SYSTEMS: E/o bone secondaries 
             E/o cutaneous secondaries 
 
 
 
 
 
 
 
 
 
 
INVESTIGATIONS: 
 
 
 
FIBEROPTIC BRONCHOSCOPY:  
   
  Larynx  
  Vocal cords 
  Trachea  
  Carina  
  Bronchi  
 
 
 
BIOPSY:  
 
  Cells  
  Nuclei  
 
 Impression  
   
 
STAGING: 
  Tumour  
 
  Node 
  
  Metastasis 
   
  STAGE:  
IMAGING  
X-ray chest PA view 
 
CT-thorax     
Lobes 
Nodes  
Pleura  
Mediastinum  
Diaphragm  
Pericardium & other features  
Ultrasound abdomen& pelvis : Liver 
                                                Adrenals   
                                                Others:  
 
 
 
 
 
 
 
Note: 
Recurrent laryngeal.n. palsy 
Phrenic nerve palsy 
Pancoast tumour 
Horner syndrome 
Chest wall invasion 
Pleural effusion 
SVC obstruction 
Dysphagia 
Pericardial effusion 
 
Bone secondaries 
Liver secondaries 
Brain secondaries 
 
Paraneoplastic syndrome 
GLOSSARY 
 
 
 
BAC    Bronchoalveolar carcinoma 
 
COPD    Chronic obstructive pulmonary disease 
 
CXR    Chest X ray 
 
CT    Computed tomography 
 
GRH    Government Rajaji Hospital 
 
HPOA   Hypertrophic Pulmonary Osteoarthropathy 
 
NSCLC   Non small cell lung carcinoma 
 
PAA    Para aortic adenopathy 
 
SCLC    Small cell lung carcinoma 
 
SPN    Solitary pulmonary nodule 
 
SIADH   Syndrome of inappropriate secretion of Antidiuretic  
    hormone 
 
SVCO    Superior venacaval obstruction 
 
TTNA    Transthoracic needle aspiration 
 
TNM    Tumour Node Metastasis 
 
 
 
 
FIGURE 1. CUTANEOUS SECONDARIES IN CA LUNG 
 
 
FIG.1A 
 
FIG.1B 
 
GRH- Madurai 
GRH- Madurai 
FIGURE 2. GRADE IV HYPERTROPHIC PULMONARY 
OSTEOARTHROPATHY 
 
 
FIGURE 3.  BONE SECONDARIES 
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FIGURE 4 RIGHT UPPER LOBE LUNG CANCER 
 
FIGURE 5. LUNG CANCER IN OLD TUBERCULOSIS 
 
GRH- Madurai 
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FIGURE 6.  CENTRAL BRONCHOGENIC CARCINOMA 
 WITH PLEURAL EFFUSION 
                             
 
 
FIGURE 7. PLEURAL SECONDARY NODULES 
 IN CA LUNG 
                         
 
FICURE 8. BRAIN  SECONDARIES  FROM   
LUNG  CARCINOMA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 9. BRONCHOSCOPE 
 
 
FIGURE 10. RIGHT MAIN BROCHUS SHOWING 
 GROWTH- BRONCHOSCOPIC VIEW 
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